CN110123871B - Traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and preparation method thereof - Google Patents
Traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and preparation method thereof Download PDFInfo
- Publication number
- CN110123871B CN110123871B CN201910474050.6A CN201910474050A CN110123871B CN 110123871 B CN110123871 B CN 110123871B CN 201910474050 A CN201910474050 A CN 201910474050A CN 110123871 B CN110123871 B CN 110123871B
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- preparation
- medicine composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims description 42
- 238000002360 preparation method Methods 0.000 title abstract description 38
- 239000003053 toxin Substances 0.000 title description 14
- 231100000765 toxin Toxicity 0.000 title description 14
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 10
- 235000004347 Perilla Nutrition 0.000 claims description 9
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 240000007124 Brassica oleracea Species 0.000 claims description 5
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 5
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 3
- 241000565356 Fraxinus pennsylvanica Species 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 201000002364 leukopenia Diseases 0.000 abstract description 9
- 231100001022 leukopenia Toxicity 0.000 abstract description 9
- 206010008570 Chloasma Diseases 0.000 abstract description 7
- 208000003351 Melanosis Diseases 0.000 abstract description 7
- 206010037549 Purpura Diseases 0.000 abstract description 7
- 241001672981 Purpura Species 0.000 abstract description 7
- 230000002411 adverse Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 231100000167 toxic agent Toxicity 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract description 2
- 238000007599 discharging Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 14
- 238000002512 chemotherapy Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 240000006122 Chenopodium album Species 0.000 description 2
- 235000009344 Chenopodium album Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A Chinese medicinal composition for increasing leukocyte and removing toxic substance is prepared from Perillae herba and herba Chenopodii Serotini. It can be made into capsule, tablet, granule and oral liquid. By the optimized preparation process, the effective components in the medicinal materials are fully extracted, and the effects of increasing leucocytes and blood platelets, improving blood circulation, discharging vivotoxin and enhancing the immune function of the organism are achieved by compatibility. Can be used for treating leukopenia, purpura, chloasma, etc., with good therapeutic effect and no adverse side effects.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof, belonging to the field of traditional Chinese medicines.
Background
Leukopenia is mainly referred to as neutropenia. Neutrophils are the major component of leukocytes, so neutropenia often leads to leukopenia when leukocytes are below 4.0X 109the/L is called leukopenia. Leukopenia and neutropenia are one of the most common complications of malignant tumor patients receiving chemotherapy, and chemotherapy-related leukopenia patients are easy to generate fever and multiple infections, have reduced resistance and cannot tolerate chemotherapy. Thrombocytopenic purpura is an immune syndrome, and is characterized in that excessive platelet destruction causes purpura, pigmentation is a skin phenomenon, is caused by endocrine balance and the like, almost everyone has the purpura, the drug treatment method mainly discharges vivotoxin, the symptoms are closely related to blood, the treatment drugs for the diseases are few, most of the drugs have large side effects on human bodies, and the traditional Chinese medicine treatment adopts a method of treatment based on syndrome differentiation and combined application of reinforcement and elimination, so that the disease resistance of the body is improved, the blood circulation condition of the whole body and the quantity of leucocytes and platelets are improved, and the finding of a drug with small side effect and good curative effect is also the focus of attention of people.
The invention develops the traditional Chinese medicine composition preparation with the functions of increasing leucocytes and blood platelets and expelling toxin by optimizing the medicine composition and the proportion, and lays a solid foundation for the research and development of new medicines.
Disclosure of Invention
The invention relates to a traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof.
In order to achieve the purpose, the technical scheme provided by the invention is as follows: a traditional Chinese medicine composition preparation for improving leucocyte and detoxifying function and a preparation method thereof are characterized in that the raw material medicines comprise the following components in parts by weight: purple perilla 100-300 and red ash vegetable 100-300.
A traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof are disclosed, wherein the preferable weight parts are as follows: purple perilla 200 and red kale 200.
A Chinese medicinal composition preparation for improving leukocyte and removing toxic substance and its preparation method comprise the following steps:
(1) weighing Perillae herba and herba Chenopodii Serotini, pulverizing, adding 4L clear water into casserole, decocting for 2 hr, filtering, adding 3L clear water into the medicinal materials, decocting for 2 hr, filtering, mixing decoctions, and concentrating to relative density of 1.20-1.25;
(2) adding a proper amount of conventional auxiliary materials into the mixture obtained in the step (1), and uniformly mixing to obtain the traditional Chinese medicine.
The preparation of the invention is characterized by comprising capsules, tablets, granules and oral liquid.
The invention has the beneficial effects that: the invention provides a Chinese medicinal composition preparation for improving leucocyte and expelling toxin and a preparation method thereof. Can be used for treating leukopenia, purpura, chloasma, etc., with good therapeutic effect and no adverse side effects.
Detailed Description
Example 1
A traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof are disclosed, wherein the raw material medicines comprise the following components in parts by weight: purple perilla 200 and red kale 200.
(1) Weighing Perillae herba and herba Chenopodii Serotini, pulverizing, adding 4L clear water into casserole, decocting for 2 hr, filtering, adding 3L clear water into the medicinal materials, decocting for 2 hr, filtering, mixing decoctions, and concentrating to relative density of 1.20-1.25;
(2) adding a proper amount of conventional auxiliary materials into the mixture obtained in the step (1), and uniformly mixing to obtain the traditional Chinese medicine.
Example 2
A traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof are disclosed, wherein the raw material medicines comprise the following components in parts by weight: purple perilla 100 and red kale 300.
The procedure was as in example 1.
Example 3
A traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof are disclosed, wherein the raw material medicines comprise the following components in parts by weight: purple perilla 300 and red kale 100.
The procedure was as in example 1.
Example 4
A traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof are disclosed, wherein the raw material medicines comprise the following components in parts by weight: perilla frutescens 150 and red chenopodium album 250.
The procedure was as in example 1.
Comparative example 1
Sanguisorba officinalis L tablet is sold in market.
Comparative example 2
A traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof are disclosed, wherein the raw material medicines comprise the following components in parts by weight: and (5) purple perilla 200.
The procedure was as in example 1.
Comparative example 3
A traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and a preparation method thereof are disclosed, wherein the raw material medicines comprise the following components in parts by weight: red chenopodium album (lour.) harms 200.
The procedure was as in example 1.
The animal experiment method and conclusion of the traditional Chinese medicine composition preparation of the invention are as follows:
healthy rats (male and female halves) were fed normally for 7 days, and then 10 mg/100 g of Cyclophosphamide (CTX) was injected into the abdominal cavity of the rat, and 100. mu.L of blood was drawn from the tail of the rat before and 3 days after the injection of CTX using a 1mL sterile syringe (heparin pretreatment), and the blood routine was determined. White blood cell and platelet-reduced rats, 10 per group, were selected and divided into model groups, examples 1-4 groups and comparative examples 1-3 groups, and 10 healthy rats were taken as normal control groups. The model group and the normal control group were administered with a corresponding volume of distilled water, and the groups of examples 1 to 4 and the groups of comparative examples 1 to 3 were administered with the drugs of the respective components in an amount of 1g/kg 2 times per day. After 10 days of continuous administration, blood was collected and blood routine was determined, wherein White Blood Cells (WBC) and Platelets (PLT) in rats were determined as shown in tables 1-2. Experimental results show that the examples 1-4 can obviously improve the concentration of white blood cells and platelets of rats.
Table 1: concentration of white blood cells in rat
Comparison with model groups: p < 0.01 > and P < 0.05
Table 2: concentration of rat platelets
Comparison with model groups: p < 0.01 > and P < 0.05
The mice were randomly divided into groups of 10 mice each, examples 1-4, comparative examples 1-3, normal group, model group. Examples 1 to 4, comparative examples 1 to 3 and model groups were each injected with 20 mg/kg of progesterone injection, normal groups were each injected with 0.1ml/20g of sterile water for injection, 1 day was taken by injecting each group to the back of the tail of the mouse, while the medium-wave ultraviolet rays were irradiated for 30 minutes, and the mice of each group were intragastrically administered while molding, 1g/kg of the drug of the corresponding group was administered to examples 1 to 4 and comparative examples 1 to 3, and 0.1ml/20g of purified water was administered to the model groups and normal groups 1 day for 35 consecutive days. Animals were sacrificed 2 hours after the last administration on day 35, and appropriate amounts of skin and liver tissues at the site irradiated with ultraviolet rays were taken, homogenized in ice bath to 10% tissue, centrifuged to obtain supernatant, and MDA, tyrosine and lipofuscin levels of skin were measured, skin tissues at the irradiated site (about 1.0cm × 1.0 cm), fixed with 10% formalin, sliced by conventional paraffin embedding, and dewaxed to water and antigen retrieval, and then melanin granules in epidermis were visualized by immunohistochemistry using HMB45 (melanoma) as a primary antibody to observe the distribution of melanocytes in epidermis, and the measurement results are shown in table 3. The results show that the examples 1-4 can obviously reduce the MDA, the melanocyte number, the tyrosine and the lipofuscin level in the skin of the mouse, and the formula has the effect of expelling toxin.
Table 3: measurement of MDA, tyrosine, lipofuscin and melanocyte number in mouse skin
Comparison with model groups: p < 0.01
Clinical experiment method and conclusion of traditional Chinese medicine composition preparation
In the treatment process of leukopenia, purpura and chloasma in the chemotherapy process, the difference between men and women is not large, the leucocyte and the platelet of a patient can be obviously improved, and the chloasma can be effectively removed.
The granules prepared in example 1 were selected at 5g per bag. Orally administered twice a day, 1 bag each time.
Case 1:
ning somebody, after the operation of lung cancer of 51 years old, men and women need to be treated with chemotherapy, and after 1 time of chemotherapy, symptoms of inappetence, myasthenia of limbs, insomnia and dreaminess appear. The leucocyte and the platelet are obviously reduced by detection, the second chemotherapy can not be carried out, after the granular formulation prepared by the pharmaceutical composition is taken for 10 days, the symptom is obviously improved, the spirit of people is much, after the detection, the leucocyte and the platelet are basically recovered to be normal, and the granular formulation is taken while the second chemotherapy is carried out, the symptom after the first chemotherapy does not appear.
Case 2:
in Sunzhi, 44 years old, women, large ecchymosis and hematoma on legs are uniformly distributed, bleeding occurs frequently in noses and gums, skins are easy to be bluish purple, intolerant of cold, menorrhagia and abnormal hemogram after collision, thrombocytopenic purpura is detected by a hospital, symptoms are improved after hospitalization, and the symptoms are reappeared after discharge.
Case 3:
the granules prepared by taking the pharmaceutical composition of the invention are taken for one month, the symptoms are obviously improved, the chloasma basically disappears after three months of taking, and the gas color is also obviously improved.
The animal experiments and clinical experiments show that the traditional Chinese medicine composition preparation provided by the invention achieves unexpected technical effects on treatment of leukopenia, purpura and chloasma in the chemotherapy process compared with the existing products in the prior art by adopting specific raw material medicine combinations and dosage, and has the effects of obviously improving leucocytes and platelets and treating purpura and chloasma.
Example 5 preparation of capsules:
steps (1) to (2) were the same as in example 1;
and (3) drying the mixture obtained in the step (2), crushing, sterilizing and encapsulating to obtain the capsule.
Example 6 preparation of tablets:
steps (1) to (2) were the same as in example 1;
and (3) drying the mixture obtained in the step (2), sterilizing and tabletting to obtain the tablet.
Example 7 preparation of granules:
steps (1) to (2) were the same as in example 1;
and (3) granulating the mixture obtained in the step (2), sterilizing and bagging to obtain the compound feed.
Example 8 preparation of oral liquid:
steps (1) to (2) were the same as in example 1;
and (3) adding water into the mixture obtained in the step (2) to a constant volume of 50ml, uniformly mixing, filling and sterilizing to obtain the traditional Chinese medicine.
The above description is illustrative of the present invention and is not intended to be limiting, and any simple modifications of the present invention are intended to fall within the scope of the present invention.
Claims (3)
1. The application of a traditional Chinese medicine composition in preparing a medicine for increasing the concentration of white blood cells is characterized in that the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 100 portions of perilla and 300 portions of red ash, wherein the traditional Chinese medicine composition is prepared by the following steps:
weighing purple perilla and red lima, crushing, adding 4L of clear water into an earthen pot, decocting for 2 hours, filtering, adding 3L of clear water into the medicinal materials, continuing to decoct for 2 hours, filtering, combining the decoction and concentrating until the relative density is 1.20-1.25;
and (2) adding a proper amount of conventional auxiliary materials into the mixture obtained in the step (1), and uniformly mixing to obtain the traditional Chinese medicine.
2. The use of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: purple perilla 200 parts and red kale 200 parts.
3. The use according to claim 1 or 2, wherein the Chinese medicinal composition is formulated as a capsule, tablet, granule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910474050.6A CN110123871B (en) | 2019-06-02 | 2019-06-02 | Traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910474050.6A CN110123871B (en) | 2019-06-02 | 2019-06-02 | Traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110123871A CN110123871A (en) | 2019-08-16 |
| CN110123871B true CN110123871B (en) | 2021-08-17 |
Family
ID=67579783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910474050.6A Active CN110123871B (en) | 2019-06-02 | 2019-06-02 | Traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110123871B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107260800A (en) * | 2017-05-27 | 2017-10-20 | 桦南仙紫食品科技有限公司 | Resveratrol purple perilla soft capsule and preparation method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225162B (en) * | 2011-05-31 | 2012-08-29 | 邢春丽 | Medicine for enhancing leukocyte and thrombocyte of human body |
| CN109091530B (en) * | 2017-06-21 | 2021-10-22 | 中国医学科学院药物研究所 | Application of perilla leaf extract in prevention or treatment of aplastic anemia |
-
2019
- 2019-06-02 CN CN201910474050.6A patent/CN110123871B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107260800A (en) * | 2017-05-27 | 2017-10-20 | 桦南仙紫食品科技有限公司 | Resveratrol purple perilla soft capsule and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110123871A (en) | 2019-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515615A (en) | Herbal composition for prostate symptoms | |
| JP2019501912A (en) | Use of citrus extract and isoacteoside in muscle protection | |
| CN103446525A (en) | Traditional Chinese medicine composition for treating skin diseases as well as preparation method and application of traditional Chinese medicine composition | |
| CN102302608B (en) | Chinese medicinal composition for treating anemia and preparation method thereof | |
| CN101732413B (en) | Chinese medicinal composition for treating arthromyodynia and preparation method thereof | |
| CN110123871B (en) | Traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and preparation method thereof | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN104688723B (en) | Application of icaritin in preparation of medicine for treating anemia | |
| CN103417799B (en) | A kind of application of Chinese medicine composition in the medicine for preparing treatment anaemia | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| US20100285163A1 (en) | Composition for Treating or Preventing Hot Flashes and use Thereof | |
| KR101911877B1 (en) | Functional food composition comprising herbal medicinal extracts | |
| CN104524292A (en) | Application of traditional Chinese medicine preparation in preparation of medicament for treating obesity | |
| CN111298061B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, removing stasis and resolving masses and preparation method thereof | |
| CN101721612B (en) | Chinese medicinal composition for raising leucocytes and preparation method and application thereof | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN104547738A (en) | Traditional Chinese medicine preparation for treating obesity and preparation method of traditional Chinese medicine preparation | |
| CN108815342B (en) | Traditional Chinese medicine composition for treating male infertility | |
| CN108721572A (en) | A kind of Chinese medicine composition for treating liver cancer and hepatic sclerosis | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN103655856B (en) | A kind of Chinese medicine composition for the treatment of the anti-tumor of removing toxic substances of chronic leukemia | |
| CN104107325A (en) | Medicinal composition with effect of improving memory and preparation method of medicinal composition | |
| CN117731749B (en) | A Chinese medicine composition for treating cancer pain and its preparation method and application | |
| KR20190101632A (en) | Anti-inflammatory composition containing medicinal herbs | |
| CN112168934A (en) | Chinese medicine compound granule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |